The blood screen testing market is apparently plateauing, with risks of decline over the next few years, as more patents expire. Additionally, there have been structural industry changes that could accelerate this, particularly the acquisition of Gen-Probe by Hologic. The acquisition also affects Novartis in the nucleic acid testing part of the business. However, there are many untapped markets and many regions where blood donations themselves should be higher to have modern public health. This report shows that the future market for blood screening should be very robust for those firms that pursue the right regions with the right products.